Evidence map›Paper›PMID 33902047›Full record

ArticleNeuro-degenerative diseases2020

The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.

Iona Pearson, Stella A Glasmacher, Judith Newton, Emily Beswick, Arpan R Mehta, Richard Davenport, Siddharthan Chandran, Suvankar Pal, CARE-MND consortium

Abstract read
In one paragraph

Article in Neuro-degenerative diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Iona PearsonCollege of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Stella A GlasmacherCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Judith NewtonCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Emily BeswickCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Arpan R MehtaCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Richard DavenportAnne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Siddharthan ChandranCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Suvankar PalCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
CARE-MND consortium

Funding

Medical Research Council MR/R001162/1Motor Neurone Disease Association MEHTA/JUL17/948-795
6 · The paper itself

Abstract

introductionSaliva problems are common and distressing for people with motor neuron disease (pwMND). Despite clinical guidelines for assessment and treatment, management of saliva problems has received little research attention.

objectiveWe aimed to investigate the prevalence of saliva problems in pwMND, their association with clinical factors, and their management practice using a highly curated population-based register for motor neuron disease (MND) with 99% case ascertainment.

methodsWe conducted an analysis of pwMND diagnosed between January 2015 and October 2019 using the Scottish MND Register (CARE-MND [Clinical, Audit, Research, and Evaluation of MND]). The association between clinical factors and saliva problems was investigated using univariate and multivariable logistic regression; results are reported as odds ratio (OR) and 95% confidence intervals. A survey of health-care professionals involved in the care of pwMND was performed to contextualize the findings.

results939 pwMND were included. Prevalence of saliva problems was 31.3% (294). Bulbar onset (OR 9.46 [4.7, 19.2]; p < 0.001) but not age, sex, time to diagnosis, or MND subtype were independently associated with the presence of saliva problems in multivariable regression, and 52.7% (155) of those with saliva problems received pharmacological management. The most commonly used medications were hyoscine, amitriptyline, carbocisteine, glycopyrrolate, and atropine. Evidence base (8, 72.7%) and local guidelines (10, 90.9%) were cited as the most important factors influencing treatment decision by survey respondents (n = 11).

conclusionSaliva problems are common and associated with bulbar onset MND. A substantial proportion of pwMND with saliva problems did not receive recommended treatments. Future research is required to determine the relative efficacy of individual pharmacological treatments.

Indexed as

Amyotrophic Lateral SclerosisMotor Neuron DiseaseHumansPrevalenceSalivaScotlandHypersalivationMotor neuron diseaseSaliva problem

Identifiers

PMID33902047
PMCPMC7610776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.